

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Equality and health inequalities assessment (EHIA)

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality and health inequalities assessment (EHIA) template

The use of hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS)

The considerations and potential impact on equality and health inequalities have been considered throughout the guidance development, maintenance and update process according to the principles of the NICE equality policy and those outlined in [Developing NICE guidelines: the manual](#).

This EHIA relates to:

the use of hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS) and it impacts the guidelines on [ovarian cancer: recognition and initial management](#) (2011) NICE guideline CG122; on [colorectal cancer](#) (2020) NICE guideline NG151; and on [oesophago-gastric cancer: assessment and management in adults](#) (2018) NICE guideline NG83.

Appendix A: equality and health inequalities assessment (EHIA)

2023 exceptional surveillance of Ovarian cancer: recognition and initial management, Colorectal cancer, and Oesophago-gastric cancer: assessment and management in adults (NICE guideline CG122, NG151 and NG83)

STAGE 1. Surveillance review

Date of surveillance review: February 2024

Focus of surveillance review: the use of hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS)

Exceptional review

1.1 On reviewing the existing EIA or EHIA and issues log for the guideline(s) and quality standard(s), describe below any equality and health inequalities issues relevant to the current surveillance review

No related issues were identified in the EIA for NICE guideline CG122. No related issues were identified in the EIA for NICE guideline NG151. No related issues were identified in the EIA for NICE guideline NG83.

1.2 Did you identify any equality and health inequalities issues through initial intelligence gathering (for example, national policy documents, topic expert/patient group feedback, evidence searches, implementation data)?
--

No equality and health inequalities issues were identified during this surveillance review.

1.3 If you have consulted stakeholders or topic experts, what questions did you ask about equality and health inequalities issues?

One stakeholder raised the fact that older and more frail people may not benefit from HIPEC as it is not clinically appropriate for this population.

1.4 What equality and health inequalities issues have been identified during this surveillance review and what was the impact on the current review and outcome decision? [If an update is proposed, include information in the update and outcomes plan]

No equality and health inequalities issues were identified during this surveillance review.

Completed by surveillance reviewer: SP, Technical Analyst

Date: February 2024

Approved by NICE surveillance associate director: KN, associate director

Date: February 2024

ISBN: 978-1-4731-6777-3